Filtered By:
Condition: Ischemic Stroke
Therapy: Statin Therapy

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 1639 results found since Jan 2013.

Rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke: the Japan Statin Treatment Against Recurrent Stroke (J‐STARS)
ConclusionThis article reports the rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke. Follow‐ups of patients are in progress and will end in 2014.
Source: International Journal of Stroke - September 9, 2013 Category: Neurology Authors: Yoji Nagai, Tatsuo Kohriyama, Hideki Origasa, Kazuo Minematsu, Chiaki Yokota, Shinichiro Uchiyama, Setsuro Ibayashi, Yasuo Terayama, Makoto Takagi, Kazuo Kitagawa, Eiichi Nomura, Naohisa Hosomi, Toshiho Ohtsuki, Takemori Yamawaki, Yoshihiro Matsubara, Mas Tags: Research Source Type: research

Incidence, Trends, and Predictors of Ischemic Stroke 1 Year After an Acute Myocardial Infarction Clinical Sciences
Conclusions— The risk of ischemic stroke within a year after myocardial infarction is substantial but has clearly been reduced during the studied time period. The major predictive factors found to correlate well with previous investigations. Reperfusion treatment, thrombocyte aggregation inhibition, and lipid lowering are the main contributors to the observed risk reduction.
Source: Stroke - October 27, 2014 Category: Neurology Authors: Ulvenstam, A., Kajermo, U., Modica, A., Jernberg, T., Soderstrom, L., Mooe, T. Tags: Platelet function inhibitors, Acute myocardial infarction, Acute Cerebral Infarction, Platelets Clinical Sciences Source Type: research

Web-based tool for dynamic functional outcome after acute ischemic stroke and comparison with existing models
Background: Acute ischemic stroke (AIS) is one of the leading causes of death and adult disability worldwide. In the present study, we aimed to develop a web-based risk model for predicting dynamic functional status at discharge, 3-month, 6-month, and 1-year after acute ischemic stroke (Dynamic Functional Status after Acute Ischemic Stroke, DFS-AIS). Methods: The DFS-AIS was developed based on the China National Stroke Registry (CNSR), in which eligible patients were randomly divided into derivation (60%) and validation (40%) cohorts. Good functional outcome was defined as modified Rankin Scale (mRS) score???2 at discharge...
Source: BMC Neurology - November 25, 2014 Category: Neurology Authors: Ruijun JiWanliang DuHaipeng ShenYuesong PanPenglian WangGaifen LiuYilong WangHao LiXingquan ZhaoYongjun WangOn behalf of China National Stroke Registry (CNSR) investigators Source Type: research

Statins and the risks of stroke recurrence and death after ischemic stroke: The Fukuoka Stroke Registry
This study aimed to elucidate whether prescribed doses of statins reduce the risks of cerebrovascular events (CVEs: stroke recurrence or transient ischemic attack) and all-cause mortality in a cohort of Japanese patients with first-ever ischemic stroke.Methods: The 2822 eligible patients registered in the Fukuoka Stroke Registry with first-ever acute ischemic stroke from June 2007 to February 2011 were classified into statin users (n = 993) and non-users (n = 1829) at discharge, and followed up until March 2012. We assessed the cumulative risks of CVE and all-cause mortality by the Kaplan–Meier method, and calculated...
Source: Atherosclerosis - November 25, 2013 Category: Cardiology Authors: Noriko Makihara, Masahiro Kamouchi, Jun Hata, Ryu Matsuo, Tetsuro Ago, Junya Kuroda, Takahiro Kuwashiro, Hiroshi Sugimori, Takanari Kitazono, Fukuoka Stroke Registry Investigators Tags: Clinical & Population Research – Intervention Source Type: research

Implementation of a Structured Guideline-Based Program for the Secondary Prevention of Ischemic Stroke in China Clinical Sciences
Conclusions— The implementation of a program to improve adherence to secondary ischemic stroke prevention efforts in China is feasible, but these programs had only a limited impact on adherence and no impact on 1-year outcomes. Further development of a structured program to reduce vascular events after stroke is needed. Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00664846.
Source: Stroke - January 27, 2014 Category: Neurology Authors: Peng, B., Ni, J., Anderson, C. S., Zhu, Y., Wang, Y., Pu, C., Wu, J., Wang, J., Zhou, L., Yao, M., He, J., Shan, G., Gao, S., Xu, W., Cui, L., on behalf of the SMART Investigators Tags: Secondary prevention Clinical Sciences Source Type: research

Statin therapy in acute ischemic stroke: Time for large randomized trials?
Despite improvements in stroke mortality coupled with therapeutic advances, stroke patients often face the prospect of substantial disability. Novel strategies are clearly needed to further improve stroke outcomes. These might include new indications for previously licensed drugs proven effective and safe in related disease processes,1 such as statins. Unlike strong evidence supporting statin use in cardiovascular risk reduction and acute myocardial ischemia, their effects on cerebral tissue and potential benefits on stroke outcomes remain poorly understood and understudied. The only current stroke-specific indication for ...
Source: Neurology - March 21, 2016 Category: Neurology Authors: Charidimou, A., Merwick, A. Tags: All Cerebrovascular disease/Stroke, Infarction EDITORIALS Source Type: research

Impact of Increased Early Statin Administration on Ischemic Stroke Outcomes: A Multicenter Electronic Medical Record Intervention Stroke
Conclusions A simple EMR change increased early statin administration in ischemic stroke and was associated with improved clinical outcomes. This is, to our knowledge, the first EMR intervention study to show that a modification of an electronic order set resulted in improved clinical outcomes.
Source: JAHA:Journal of the American Heart Association - July 28, 2016 Category: Cardiology Authors: Flint, A. C., Conell, C., Klingman, J. G., Rao, V. A., Chan, S. L., Kamel, H., Cullen, S. P., Faigeles, B. S., Sidney, S., Johnston, S. C. Tags: Ischemic Stroke, Neuroprotectants Source Type: research

Yield of Dual Therapy With Statin and Ezetimibe in the Treat Stroke to Target Trial
CONCLUSIONS: In the TST trial (Treat Stroke to Target), targeting an LDL cholesterol of < 70 mg/dL with a combination of statin and ezetimibe compared with 100±10 mg/dL consistently reduced the risk of subsequent stroke.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT01252875. URL: clinicaltrialsregister.eu; Unique identifier: EUDRACT2009-A01280-57.PMID:36154103 | DOI:10.1161/STROKEAHA.122.039728
Source: Atherosclerosis - September 26, 2022 Category: Cardiology Authors: Pierre Amarenco Jong S Kim Julien Labreuche Hugo Charles Maurice Giroud Byung-Chul Lee Philippa C Lavall ée Marie-H élène Mahagne Elena Meseguer Norbert Nighoghossian Philippe Gabriel Steg Éric Vicaut Eric Bruckert Treat Stroke to Target Investigators Source Type: research

Differences in lipid profiles in two Hispanic ischemic stroke populations
ConclusionWe found significant differences in lipid fractions in Hispanic ischemic stroke patients, with lower total cholesterol and low‐density lipoprotein, and higher triglyceride levels in Mexicans. These findings highlight the heterogeneity of dyslipidemia among the Hispanic race‐ethnic group and may lead to different secondary prevention strategies.
Source: International Journal of Stroke - December 20, 2013 Category: Neurology Authors: A. Arauz, J. G. Romano, A. Ruiz‐Franco, T. Shang, C. Dong, T. Rundek, S. Koch, B. Hernández‐Curiel, J. Pacheco, P. Rojas, F. Ruiz‐Navarro, M. Katsnelson, R. L. Sacco Tags: Research Source Type: research

The Effect Of Statin Pretreatment And Serum Lipid Values On Hemorragic Conversion After rt-PA for Acute Ischemic Stroke (P4.225)
CONCLUSIONS:Our study showed no significant correlation between PSS or lipid profile with ICH following IVT. Furthermore, no association with DmRS was found. Additional larger studies on PSS may be beneficial to determine the effects of statins on ICH risk.Disclosure: Dr. Khawaja has nothing to disclose. Dr. Lyerly has nothing to disclose. Dr. Kumar has nothing to disclose. Dr. Sands has nothing to disclose. Dr. Bavarsad Shahripour has nothing to disclose. Dr. Alexandrov has received personal compensation for activities with Genentech, Inc.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Khawaja, A., Lyerly, M., Kumar, G., Sands, K., Bavarsad Shahripour, R., Alexandrov, A. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Thrombolysis Source Type: research

Atherogenic Dyslipidemia and Residual Cardiovascular Risk in Statin-Treated Patients Clinical Sciences
Conclusions— The presence of atherogenic dyslipidemia was associated with higher residual cardiovascular risk in PERFORM and SPARCL subjects with stroke or transient ischemic attack receiving statin therapy. Specific therapeutic interventions should now be trialed to address this residual risk.
Source: Stroke - April 28, 2014 Category: Neurology Authors: Sirimarco, G., Labreuche, J., Bruckert, E., Goldstein, L. B., Fox, K. M., Rothwell, P. M., Amarenco, P., on behalf of the PERFORM and SPARCL Investigators and Committees, Bousser, Chamorro, Ford, Fox, Fisher, Hennerici, Mattle, Rothwell, Callahan, Goldste Tags: Acute Cerebral Infarction, Primary and Secondary Stroke Prevention, Other Stroke Treatment - Medical, Transient Ischemic Attacks Clinical Sciences Source Type: research

Occurrence and Predictors of Persistent Impaired Glucose Tolerance After Acute Ischemic Stroke or Transient Ischemic Attack
Conclusions: Half of the patients with impaired glucose tolerance after a TIA or ischemic stroke have persistent impaired glucose tolerance. We provide a prediction model to identify patients at risk of persistent impaired glucose tolerance, with statin use, triglyceride, and fasting plasma glucose as the most important predictors, which after external validation might be used to optimize secondary prevention.
Source: Journal of Stroke and Cerebrovascular Diseases - April 10, 2014 Category: Neurology Authors: Susanne Fonville, Heleen M. den Hertog, Adrienne A.M. Zandbergen, Peter J. Koudstaal, Hester F. Lingsma Tags: Original Articles Source Type: research

Safety of Statin Pretreatment in Intravenous Thrombolysis for Acute Ischemic Stroke Brief Reports
Conclusions— Statin pretreatment seems not to be associated with adverse outcomes in AIS patients treated with IVT. The effect of statin pretreatment on early functional outcomes in thrombolysed AIS patients deserves further investigation.
Source: Stroke - August 24, 2015 Category: Neurology Authors: Tsivgoulis, G., Kadlecova, P., Kobayashi, A., Czlonkowska, A., Brozman, M., Švigelj, V., Csiba, L., Korv, J., Demarin, V., Vilionskis, A., Jatuzis, D., Katsanos, A. H., Rudolf, J., Krespi, Y., Mikulik, R. Tags: Thrombolysis Brief Reports Source Type: research

Impact of Increased Early Statin Administration on Ischemic Stroke Outcomes: A Multicenter Electronic Medical Record Intervention Stroke
We examined the relationship between intervention and outcome using autoregressive integrated moving average (ARIMA) time‐series modeling. The EMR intervention increased both overall in‐hospital statin administration (from 87.2% to 90.7%, P
Source: JAHA:Journal of the American Heart Association - July 28, 2016 Category: Cardiology Authors: Flint, A. C., Conell, C., Klingman, J. G., Rao, V. A., Chan, S. L., Kamel, H., Cullen, S. P., Faigeles, B. S., Sidney, S., Johnston, S. C. Tags: Ischemic Stroke, Neuroprotectants Original Research Source Type: research

Challenges in the Medical Management of Symptomatic Intracranial Stenosis in an Urban Setting Clinical Sciences
Background and Purpose—Since the SAMMPRIS trial (Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis), aggressive medical management (AMM), which includes dual antiplatelet therapy (DAPT) and high-dose statin (HDS) therapy, is recommended for patients with symptomatic intracranial atherosclerotic disease. However, limited data on the real-world application of this regimen exist. We hypothesized that recurrent stroke risk among patients treated with AMM is similar to the medical arm of the SAMMPRIS cohort.Methods—Using a prospective registry, we identified all patients adm...
Source: Stroke - July 24, 2017 Category: Neurology Authors: Rajbeer S. Sangha, Andrew M. Naidech, Carlos Corado, Sameer A. Ansari, Shyam Prabhakaran Tags: Cerebrovascular Disease/Stroke, Ischemic Stroke, Stenosis, Vascular Disease Original Contributions Source Type: research